A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
← catalyst calendarNCT07791732 · readout in 1,037 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
600estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-28
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-01 | estimated | When the study began enrolling |
| Primary completion | 2029-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- High-Grade Serous Ovarian Cancer
- Endometrioid Epithelial Ovarian
Interventions
- Drug: R-DXd — also filed as DS-6000a
- Drug: Bevacizumab — also filed as AVASTIN®, MVASI
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
measured Up to approximately 6 years
Related
4568.T · their whole pipeline · Fallopian Tube Cancer readouts
4568.T's other studiesmost recently updated first
- HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Phase 3 · Active, not recruiting
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) Phase 3 · Active, not recruiting
- First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors Phase 1 · Recruiting
- A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies Phase 1/2 · Recruiting
- A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors Phase 1 · Recruiting
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed